Resection of lung cancer invading the diaphragm

Riquet, Marc; Porte, Henri; Chapelier, Alain; Brichon, Pierre-Yves; Bernard, Alain; Dujon, Antoine; Dahan, M.; Bonette, Pierre; Guidicelli, R; Jancovici, R; Monteau, Michel; Moreau, Jean-Luc; Moreau, J E; Peillon, Christophe; Bellenot, François; Faillon, Jean-Marie; Mouroux, Jérôme

doi:10.1067/mtc.2000.106522

Cited by 23 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In these patients, 5-year survival rates from 20 to 30 month have been reported with local recurrence in 23 to 40% and distant recurrence in 60 to 79% of the patients. [43][44][45]…”

Section: Lung Cancermentioning

confidence: 99%

Primary and Secondary Tumors of the Diaphragm

Baldes

Schirren

2016

Thorac cardiovasc Surg

View full text Add to dashboard Cite

show abstract

“…In these patients, 5-year survival rates from 20 to 30 month have been reported with local recurrence in 23 to 40% and distant recurrence in 60 to 79% of the patients. [43][44][45]…”

Section: Lung Cancermentioning

confidence: 99%

Primary and Secondary Tumors of the Diaphragm

Baldes

Schirren

2016

Thorac cardiovasc Surg

View full text Add to dashboard Cite

show abstract

“…There is only a small amount of reported series with T4 Inv tumours invading the diaphragm and most of them are older case series. Yokoi et al reported 5-year survival rates of 14-33% depending on depth of diaphragm invasion, while other authors showed similar outcome (63)(64)(65)(66)(67)(68).…”

Section: T4 Inv -Diaphragmmentioning

confidence: 93%

Heterogeneity of stage IIIA non-small cell lung cancer—different tumours, different nodal status, different treatment, different prognosis: a narrative review

Flury¹,

Minervini²,

Kocher³

2022

Curr Chall Thorac Surg

View full text Add to dashboard Cite

Stage IIIA non-small cell lung cancer (NSCLC) consists of a heterogeneous group of disease, ranging from small T1a tumours with ipsilateral mediastinal lymph node involvement over T3 tumours with chest wall invasion, up to T4 tumours with mediastinal invasion with or without positive hilar lymph nodes. Based on this heterogeneity, treatment approaches as well as prognosis are very dependent on specific subgroups. Therapy recommendations should be based on multidisciplinary case discussions in high volume centres including medical and radiation oncologists, pneumologists and experienced thoracic surgeons specialized in thoracic cancer surgery. Recommendations may differ from standards in highly selected cases.Therefore, independent of age, in medically fit (operable) patients with resectable stage IIIA tumours, an aggressive approach in a curative setting is key to obtain good overall survival rates. Moreover, maintaining quality of life is essential. In this narrative review the different aspects of all the subgroups of stage IIIA NSCLC and their heterogeneity as well as the variety of treatment modalities, their combined treatment approaches and survival rates are discussed. Again, the reported 5-year survival rates, ranging from 5% in patients with bulky N2 disease, up to 50% for patients with superior sulcus tumours with hilar lymph node disease, reflect the heterogeneity of stage IIIA NSCLC.

show abstract

“…Rocco et al [13] reported a 20% 5-year survival rate in 15 cases and that of T3N0M0 (n = 11) was 27%. Riquet et al [14] performed diaphragm resection in 59 cases and reported 39% of the 5-year survival rate in cases complete mediastinal lymph node dissection.…”

Section: Diaphragm Invasionmentioning

confidence: 98%

Surgical outcomes of N2 and T3-4 non-small cell lung cancer

Watanabe¹

2003

Lung Cancer

View full text Add to dashboard Cite

Resection of lung cancer invading the diaphragm

Cited by 23 publications

References 4 publications

Primary and Secondary Tumors of the Diaphragm

Primary and Secondary Tumors of the Diaphragm

Heterogeneity of stage IIIA non-small cell lung cancer—different tumours, different nodal status, different treatment, different prognosis: a narrative review

Surgical outcomes of N2 and T3-4 non-small cell lung cancer

Contact Info

Product

Resources

About